Screening for prostate cancer in a city in Japan: age-specific prostate-specific antigen cutoff thresholds

Cancer Causes Control. 2024 Apr;35(4):671-677. doi: 10.1007/s10552-023-01824-6. Epub 2023 Nov 28.

Abstract

Purpose: Older men have higher prostate-specific antigen levels than younger men. However, the current Japanese Urological Association guidelines recommend secondary screening at a cutoff value of 4.0 ng/mL, even in older men. Here, we reexamined the cutoffs for older men using a prostate screening cohort in Japan and first performed an analysis to determine the indication cutoffs for detecting positive biopsies.

Methods: Data from 68,566 prostate cancer screenings in the city in 2018 were combined with cancer registration data. The optimal prostate-specific antigen levels to predict prostate cancer in different age groups were calculated using receiver operating characteristic curves after determining whether a cancer was registered within one year of screening.

Results: At the conventional prostate-specific antigen threshold of 4.0 ng/mL, the sensitivity, specificity, and negative predictive value were 94.9%, 91.7%, and 91.7%, respectively. The optimal prostate-specific antigen cutoff values for patients aged 50-59 years, 60-69 years, 70-79 years, and over 80 years were 3.900 ng/mL, 4.014 ng/mL, 4.080 ng/mL, and 4.780 ng/mL, respectively.

Conclusions: The sensitivity and specificity of prostate cancer screening in the city were high, indicating a highly accurate screening. The prostate-specific antigen threshold was 4.78 ng/mL in patients older than 80 years. A higher prostate-specific antigen threshold may be useful in men over 80 years of age to avoid excess biopsy and reduce costs. Our results suggest that the current Japanese method of using PSA 4.0 ng/mL as a cutoff regardless of age may not be preferable for older men.

Keywords: Accuracy of screening; Prostate cancer; Prostate-specific antigen; Screening of prostate cancer.

MeSH terms

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Biopsy
  • Early Detection of Cancer
  • Humans
  • Japan / epidemiology
  • Male
  • Prostate-Specific Antigen*
  • Prostatic Neoplasms* / diagnosis
  • Prostatic Neoplasms* / epidemiology
  • Prostatic Neoplasms* / pathology
  • Sensitivity and Specificity

Substances

  • Prostate-Specific Antigen